RubrYc Therapeutics utilizes AI-driven precision antibody identification and optimization to develop targeted therapeutics for obesity, diabetes, and heart disease. Their technology addresses the challenge of creating effective treatments for complex cardiometabolic conditions by advancing hard-to-engineer antibody candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective antibody therapeutics for complex cardiometabolic diseases like obesity, diabetes, and heart disease is challenging due to the difficulty in identifying and optimizing antibodies that target the correct epitopes. Traditional antibody discovery methods often struggle to produce candidates with the desired specificity, efficacy, and developability profiles needed to address these conditions.
Solution
RubrYc Therapeutics leverages an AI-driven platform for precision antibody identification and optimization, enabling the development of targeted therapeutics for obesity, diabetes, and heart disease. Their technology employs machine learning to steer antibodies towards specific epitopes and optimize their properties, addressing the challenges associated with engineering effective antibody candidates for complex cardiometabolic conditions. This approach facilitates the rapid advancement of novel therapeutics with enhanced safety and developability profiles. The platform also supports the creation of tailored bispecific antibodies and utilizes a masking technology to improve the delivery of clinical candidates.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for obesity, diabetes, heart disease, and immuno-oncology.
Features
- AI-driven epitope steering for precise antibody targeting
- Machine learning-based antibody optimization to enhance specificity and efficacy
- Mammalian display technology for generating diverse antibody panels
- ShieldTx™ antibody masking technology for improved safety and developability
- EngageTx™ platform for optimizing CD3-based T-cell engager bispecifics
- Capability to validate difficult targets using a powerful tech stack